Hematologic Oncology | Specialty

EC Approves Maintenance Lenalidomide for Myeloma

February 24th 2017

The European Commission has expanded the indication for lenalidomide (Revlimid) to include use as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.

Goy Shares Expertise on Exciting Progress in MCL

February 24th 2017

Andre Goy, MD, discusses combination regimens and other developments in the evolving treatment landscape in mantle cell lymphoma.

CPX-351 Offers Potential Bridge to Transplant for Secondary AML

February 23rd 2017

More patients with acute myeloid leukemia could proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen.

FDA Grants Inotuzumab Ozogamicin Priority Review for ALL

February 22nd 2017

The FDA has granted a priority review designation to inotuzumab ozogamicin for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.

Dr. Herrera on Next Steps of Drug Combinations for Hodgkin Lymphoma

February 17th 2017

Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses next steps for a phase I/II study of brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) in patients with relapsed or refractory Hodgkin lymphoma.

Dr. Tallman on the State of the Science in AML Treatment

February 17th 2017

Martin S. Tallman, MD, hematologic oncologist, chief of Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the state of the science with regards to treatment of patients with acute myeloid leukemia (AML).

Dr. Neelapu on ZUMA-1 Trial Design of KTE-C19

February 17th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the ZUMA-1 trial of the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 for patients with aggressive lymphomas.

Dr. Ansell on PD-1 Inhibitors in Hodgkin Lymphoma

February 17th 2017

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses the use of PD-1 inhibitors for patients with Hodgkin lymphoma.

Dr. Straus on Ongoing Clinical Trials in Hodgkin Lymphoma

February 15th 2017

David J. Straus, MD, an internist and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials in the field of Hodgkin lymphoma.

Full FDA Approval Sought for Blinatumomab in Acute Lymphoblastic Leukemia

February 15th 2017

A supplemental biologics license application has been submitted to the FDA for the full regulatory approval of blinatumomab as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

Dr. Chaudhary on Short-Term and Long-Term Future of CAR T-Cells

February 14th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the short-term and long-term future of CAR T-cells.

Prevalence of Ph-like ALL in Adults Emphasizes Need for Targeted Clinical Trials

February 12th 2017

A recent study published in the Journal of Clinical Oncology has found that Philadelphia chromosome-like acute lymphoblastic leukemia (ALL) accounts for over 20% of all adult patients with ALL and is correlated with poor outcomes.

Dr. Reeder on Future Treatment Approaches in Aggressive Lymphomas

February 8th 2017

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses some future treatment approaches for patients with aggressive lymphomas, including diffuse large B-cell lymphoma.

Dr. Neelapu on Next Steps With KTE-C19 in Lymphoma

February 2nd 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps with KTE-C19, an anti-CD19 chimeric antigen receptor T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

Patients Say Benefits of Brentuximab Vedotin Offset Risk of Peripheral Neuropathy

January 31st 2017

Patients with lymphoma who are treated with brentuximab vedotin (BV) often experience peripheral neuropathy as an adverse event and potentially dose-limiting toxicity. A novel study has shown that, despite the prevalence of this toxicity, these patients report that the better outcomes yielded from treatment with BV outweigh the risk of neuropathy.

Expert Discusses Ibrutinib/Palbociclib Combo in Mantle Cell Lymphoma

January 30th 2017

Peter Martin, MD, discusses the efficacy of a combination regimen of ibrutinib and palbociclib in the treatment of patients with mantle cell lymphoma.

Combining and Sequencing BCR-ABL TKIs with Omacetaxine in CML

January 21st 2017

Toxicity for Omacetaxine in CML

January 21st 2017

Experience with Omacetaxine for TKI-Resistant TKI CML

January 21st 2017

Alternative Mechanism for Treatment of Resistant CML

January 21st 2017